(KALV) Kalvista Pharmaceuticals - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.426m USD | Total Return: 134.6% in 12m
Avg Turnover: 77.8M
Qual. Beats: 0
Qual. Beats: 3
Warnings
Interest Coverage Ratio -5.0 is critical
Altman Z'' -7.36 < 1.0 - financial distress zone
Tailwinds
Supp Ema20, Leader, Tailwind, Confidence
KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for rare diseases. The company’s primary focus is hereditary angioedema (HAE), a genetic disorder characterized by severe, unpredictable swelling. Its lead candidate, sebetralstat (EKTERLY), is a plasma kallikrein inhibitor designed as an on-demand oral treatment for acute HAE attacks.
The company operates within the biotechnology sector, where business models typically involve high research and development (R&D) expenses and a reliance on the regulatory approval pipeline. Developing oral alternatives to traditional injectable therapies is a key competitive strategy in the HAE market to improve patient compliance and quality of life. KalVista is currently expanding its clinical portfolio to include pediatric formulations and disintegrating tablets.
Investors can review additional fundamental metrics and clinical trial milestones on ValueRay to further their due diligence. Headquartered in Framingham, Massachusetts, the company continues to advance its KONFIDENT clinical program to evaluate the safety and efficacy of its candidates across various patient demographics.
- FDA approval decision for sebetralstat serves as primary catalyst for commercial launch
- Oral HAE treatment market share gains versus existing injectable and subcutaneous competitors
- Clinical trial data readouts for pediatric and ODT formulations impact pipeline valuation
- Cash runway and future capital requirements dictate long-term financing and dilution risk
- Strategic partnership or acquisition interest from larger biopharmaceutical firms targeting rare diseases
| Net Income: -112.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.34 > 0.02 and ΔFCF/TA 39.38 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.11 > 3% & CFO -38.0m > Net Income -112.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.5m) vs 12m ago 1.78% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 48.82% > 50% (prev 0.0%; Δ 48.82% > 0%) |
| Interest Coverage Ratio: -5.03 > 6 (EBITDA TTM -116.0m / Interest Expense TTM 23.3m) |
| A: 0.78 (Total Current Assets 320.1m - Total Current Liabilities 57.4m) / Total Assets 335.4m |
| B: -2.27 (Retained Earnings -762.7m / Total Assets 335.4m) |
| C: -0.40 (EBIT TTM -117.4m / Avg Total Assets 293.1m) |
| D: -2.28 (Book Value of Equity -769.8m / Total Liabilities 338.1m) |
| Altman-Z'' = -7.36 = D |
As of May 24, 2026, the stock is trading at USD 26.77 with a total of 1,625,672 shares traded.
Over the past week, the price has changed by +0.22%,
over one month by +36.96%,
over three months by +72.17% and
over the past year by +134.59%.
Kalvista Pharmaceuticals has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy KALV.
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 28.6 | 6.8% |
P/S = 12.4522
P/B = 49.0328
Revenue TTM = 143.1m USD
EBIT TTM = -117.4m USD
EBITDA TTM = -116.0m USD
Long Term Debt = 139.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 15.2m USD (from shortTermDebt, last quarter)
Debt = 296.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.1m
Net Debt = 14.8m USD (calculated: Debt 296.3m - CCE 281.5m)
Enterprise Value = 1.44b USD (1.43b + Debt 296.3m - CCE 281.5m)
Interest Coverage Ratio = -5.03 (Ebit TTM -117.4m / Interest Expense TTM 23.3m)
EV/FCF = -12.77x (Enterprise Value 1.44b / FCF TTM -112.8m)
FCF Yield = -7.83% (FCF TTM -112.8m / Enterprise Value 1.44b)
FCF Margin = -78.83% (FCF TTM -112.8m / Revenue TTM 143.1m)
Net Margin = -78.59% (Net Income TTM -112.4m / Revenue TTM 143.1m)
Gross Margin = 92.24% ((Revenue TTM 143.1m - Cost of Revenue TTM 11.1m) / Revenue TTM)
Gross Margin QoQ = 93.37% (prev 92.44%)
Tobins Q-Ratio = 4.29 (Enterprise Value 1.44b / Total Assets 335.4m)
Interest Expense / Debt = 7.88% (Interest Expense 23.3m / Debt 296.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -92.7m (EBIT -117.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.88 (Total Current Assets 320.1m / Total Current Liabilities 65.6m)
Debt / Equity = -109.3 (out of range, set to none) (Debt 296.3m / totalStockholderEquity, last quarter -2.71m)
Debt / EBITDA = -0.13 (negative EBITDA) (Net Debt 14.8m / EBITDA -116.0m)
Debt / FCF = -0.13 (negative FCF - burning cash) (Net Debt 14.8m / FCF TTM -112.8m)
Total Stockholder Equity = 3.93m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.37% (Net Income -112.4m / Total Assets 335.4m)
RoE = -14.67% (Net Income TTM -112.4m / Total Stockholder Equity 766.6m)
RoCE = -12.96% (EBIT -117.4m / Capital Employed (Equity 766.6m + L.T.Debt 139.2m))
RoIC = -85.81% (negative operating profit) (NOPAT -92.7m / Invested Capital 108.1m)
WACC = 7.21% (E(1.43b)/V(1.72b) * Re(7.42%) + D(296.3m)/V(1.72b) * Rd(7.88%) * (1-Tc(0.21)))
Discount Rate = 7.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 60.0 | Cagr: 18.15%
[DCF] Fair Price = unknown (Cash Flow -112.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.09 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 4.0 | # QB: 3
EPS current Quarter (2026-06-30): EPS=-0.26 | Chg30d=+12.37% | Revisions=+20% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.23 | Chg30d=-46.87% | Revisions=+33% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.80 | Chg30d=+23.78% | Revisions=+45% | GrowthEPS=+60.5% | GrowthRev=+320.0%
EPS next Year (2027-12-31): EPS=1.20 | Chg30d=+18.99% | Revisions=+11% | GrowthEPS=+249.3% | GrowthRev=+59.7%
[Analyst] Revisions Ratio: +45%